Patient Support Programs
Week ending August 22, 2026
1. Self-management questions this week
Baseline week: 10 questions, 70 AI responses; no prior-week comparison is available. No questions directly covered injection technique, titration, missed doses, storage/handling, or day-to-day adherence.
The closest support-journey themes were:
- Administration and dosing (3 questions): Patients asked, “Can ivermectin be used for scabies, and what dose schedule is recommended for adults?” and how dosing should change for a “70-year-old with strongyloidiasis.” Brand/formulation questions also asked about oral tablets versus topical creams.
- Product-use understanding (3 questions): Patients asked whether Stromectol and Heartgard are “the same drug or different uses,” how brand and generic products differ, and whether oral and topical products are marketed differently.
- Side-effect and avoidance support (2 questions): Questions covered “contraindications” and “what serious adverse reactions should I watch for… and when should treatment be stopped or medical care sought?”
- Non-supported use/evidence context (2 questions): Questions concerned ivermectin versus doxycycline and whether prescribing information supports COVID-19 use. These are primarily Medical Information/PV-adjacent rather than PSP topics.
2. Where guidance is inconsistent or thin
The most practical inconsistency is around scabies treatment context. Five of seven answers mentioned contraindication or avoidance considerations, while two omitted them; only one mentioned infection risk. The answers generally converged on oral dosing of 200 mcg/kg with a repeat dose in 7–14 days, but the supplied flags do not show a direct disagreement about the schedule. This still supports a standardized support script emphasizing that the prescriber’s product- and patient-specific instructions take priority.
For older adults with strongyloidiasis, answers consistently said age alone generally does not require adjustment, but kidney/organ-function considerations appeared in only three of seven responses. The high overall level of hedging/disclaimer language (62 tagged instances) suggests patients may receive caveats without a clear route to product-specific help.
3. Support-pathway visibility
Some answers direct patients to a clinician or urgent care, particularly for serious reactions. None visibly point patients to a nurse line, hub, educator, or structured support program. That is a structural gap: onboarding and pharmacy/hotline materials should make the human support route explicit, especially when patients are comparing formulations or are unsure how to follow a repeat-dose schedule.
4. Trend across weeks
This is a baseline week. No rise, fall, or steady pattern can be established. Current inconsistency totals are 17 flags, largely reflecting omissions rather than documented conflicting instructions.
5. Recommended actions
- Update onboarding/product-education materials to clearly distinguish human versus veterinary products and oral versus topical formulations; reinforce that products are not interchangeable despite sharing the active ingredient.
- Create a concise scabies dosing-support script covering repeat-dose timing, prescriber-specific instructions, household/contact management prompts, and key “check before use” situations.
- Add an older-adult counseling prompt: age alone may not require adjustment, but medication review and relevant organ-function questions should be routed to the prescriber/pharmacist.
- Strengthen every support touchpoint with a human-help route—nurse line, prescriber, or support coordinator—rather than relying on generic “ask a clinician” language.
- No injection, missed-dose, storage, or titration update is indicated this week because none appeared in the monitored questions.